ijms-logo

Journal Browser

Journal Browser

Advances in Anti-inflammatory Drug Development

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 999

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biotechnology and Animal Science, National Ilan University, Yilan 26047, Taiwan
Interests: inflammation; NLRP3 inflammasome; anti-inflammatory; anti-cancer drug development
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammation is a complex set of physiological and pathological processes that can arise in any tissue in response to infectious agents and sterile disease-relevant stimuli. An abundance of new evidence demonstrates that aberrant and chronic inflammation promotes the development of a variety of diseases such as COVID-19, metabolic disorder, cancer, neurodegeneration, cardiovascular disease, and inflammatory bowel disease. Increasing evidence shows that inflammation is an imperative therapeutic target in many diseases. However, most current therapies have unmet medical needs, and better therapeutics targeting specific signaling pathways in the inflammatory response are urgently needed. This Special Issue, “Advances in Anti-inflammatory Drug Development”, welcomes original research and review articles in the field, with a focus on, but not limited to, anti-inflammatory small molecules or macromolecules produced by plants, microorganisms, animals, or chemical synthesis. Studies on inflammatory responses with a molecular and mechanistic basis, pathologies as a result of aberrant inflammation, and any interesting inflammation-related studies are also welcome.

Prof. Dr. Kuo-Feng Hua
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammation
  • inflammatory disease
  • infectious disease
  • anti-inflammatory drugs
  • innate immunity
  • cytokines
  • inflammasomes
  • sterile inflammation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 29795 KiB  
Article
Identification of Hit Compounds Using Artificial Intelligence for the Management of Allergic Diseases
by Junhyoung Byun, Junhu Tai, Byoungjae Kim, Jaehyeong Kim, Semyung Jung, Juhyun Lee, Youn woo Song, Jaemin Shin and Tae Hoon Kim
Int. J. Mol. Sci. 2024, 25(4), 2280; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms25042280 - 14 Feb 2024
Viewed by 654
Abstract
This study aimed to identify and evaluate drug candidates targeting the kinase inhibitory region of suppressor of cytokine signaling (SOCS) 3 for the treatment of allergic rhinitis (AR). Utilizing an artificial intelligence (AI)-based new drug development platform, virtual screening was conducted to identify [...] Read more.
This study aimed to identify and evaluate drug candidates targeting the kinase inhibitory region of suppressor of cytokine signaling (SOCS) 3 for the treatment of allergic rhinitis (AR). Utilizing an artificial intelligence (AI)-based new drug development platform, virtual screening was conducted to identify compounds inhibiting the SH2 domain binding of SOCS3. Luminescence assays assessed the ability of these compounds to restore JAK-2 activity diminished by SOCS3. Jurkat T and BEAS-2B cells were utilized to investigate changes in SOCS3 and STAT3 expression, along with STAT3 phosphorylation in response to the identified compounds. In an OVA-induced allergic rhinitis mouse model, we measured serum levels of total IgE and OVA-specific IgE, performed real-time PCR on nasal mucosa samples to quantify Th2 cytokines and IFN-γ expression, and conducted immunohistochemistry to analyze eosinophil levels. Screening identified 20 hit compounds with robust binding affinities. As the concentration of SOCS3 increased, a corresponding decrease in JAK2 activity was observed. Compounds 5 and 8 exhibited significant efficacy in restoring JAK2 activity without toxicity. Treatment with these compounds resulted in reduced SOCS3 expression and the reinstatement of STAT3 phosphorylation in Jurkat T and BEAS-2B cells. In the OVA-induced allergic rhinitis mouse model, compounds 5 and 8 effectively alleviated nasal symptoms and demonstrated lower levels of immune markers compared to the allergy group. This study underscores the promising nonclinical efficacy of compounds identified through the AI-based drug development platform. These findings introduce innovative strategies for the treatment of AR and highlight the potential therapeutic value of targeting SOCS3 in managing AR. Full article
(This article belongs to the Special Issue Advances in Anti-inflammatory Drug Development)
Show Figures

Figure 1

Back to TopTop